APP vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 30, 2026

APP

47.5
AI Score
VS
APP Wins

MRNA

32.3
AI Score

Investment Advisor Scores

APP

48score
Recommendation
HOLD

MRNA

32score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric APP MRNA Winner
Revenue 3.77B 534.00M APP
Net Income 2.47B -2.13B APP
Net Margin 65.6% -397.9% APP
Operating Income 2.93B -2.20B APP
ROE 78.2% -31.4% APP
ROA 29.9% -19.4% APP
Total Assets 8.27B 10.96B MRNA
Cash 3.05B 1.72B APP
Debt/Equity 1.11 0.09 MRNA
Current Ratio 4.30 2.29 APP

Relative Price Performance (Last 90 Days)

APP 1M: -9.8% · 3M: -46.0% MRNA 1M: +40.0% · 3M: +156.6%

Current Technical Phase

APP

Markdown
Sell / avoid

Price below a falling SMA50 (slope -16.4%), weak momentum, RSI 37

RSI (14): 36.8 · Price: $281.29

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

Fundamentals Snapshot

Metric APP MRNA
Market Cap — —
Forward P/E 14.1 -41.0
Trailing P/E 21.4 —
Revenue (TTM) — —
Revenue Growth 0.5% 0.0%
Gross Margin 0.9% -0.7%
Operating Margin 0.8% -5.6%
EPS 13.01 -7.36
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, APP is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.